These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31469630)

  • 1. Autoimmune hemolytic anemia, adverse event to venetoclax.
    Carriles C; Ordóñez-Fernández L; Arias-Martínez A; Menárguez-Blanc R; Rosado-María MC
    Farm Hosp; 2019 Sep; 43(5):166-167. PubMed ID: 31469630
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p).
    Lacerda MP; Guedes NR; Yamakawa PE; Pereira AD; Fonseca ARBMD; Chauffaille MLLF; Goncalves MV; Yamamoto M; Rodrigues CA
    Ann Hematol; 2017 Sep; 96(9):1577-1578. PubMed ID: 28597168
    [No Abstract]   [Full Text] [Related]  

  • 3. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
    Davids MS; Rogers KA; Tyekucheva S; Wang Z; Pazienza S; Renner SK; Montegaard J; Ihuoma U; Lehmberg TZ; Parry EM; Wu CJ; Jacobson CA; Fisher DC; Thompson PA; Brown JR
    Blood; 2022 Feb; 139(5):686-689. PubMed ID: 34788401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib: searching for a partner drug.
    Kater AP; Brown JR
    Lancet Oncol; 2019 Jan; 20(1):3-5. PubMed ID: 30522966
    [No Abstract]   [Full Text] [Related]  

  • 5. Venetoclax Data Prompt Rethink of CLL Therapy.
    Cancer Discov; 2018 Mar; 8(3):OF5. PubMed ID: 29382644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
    Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intractable autoimmune hemolytic anemia in B cell chronic lymphocytic leukemia resolved by Rituximab.
    Shvidel L; Shtalrid M; Berrebi A
    Leuk Lymphoma; 2004 Jul; 45(7):1493-4. PubMed ID: 15359657
    [No Abstract]   [Full Text] [Related]  

  • 8. [Chronic lymphocytic leukemia].
    Aoki S
    Rinsho Ketsueki; 2014 Feb; 55(2):213-22. PubMed ID: 24598189
    [No Abstract]   [Full Text] [Related]  

  • 9. A rare case of autoimmune hemolytic anemia during venetoclax therapy for relapsed chronic lymphocytic leukemia.
    Hadjiaggelidou C; Douganiotis G; Tsirou K; Verrou E; Triantafyllou T; Keramidioti K; Konstantinidou P; Katodritou E
    Leuk Lymphoma; 2021 Dec; 62(12):3054-3056. PubMed ID: 34151719
    [No Abstract]   [Full Text] [Related]  

  • 10. Venetoclax plus rituximab for chronic lymphocytic leukaemia.
    Stirrups R
    Lancet Oncol; 2018 May; 19(5):e233. PubMed ID: 29606585
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
    Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
    Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib.
    Wanner D; Bohn JP; Rudzki J; Stockhammer G; Steurer M
    Ann Hematol; 2019 Jan; 98(1):205-207. PubMed ID: 29804266
    [No Abstract]   [Full Text] [Related]  

  • 13. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
    [No Abstract]   [Full Text] [Related]  

  • 14. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial.
    Roeker LE; Woyach JA; Cheah CY; Coombs CC; Shah NN; Wierda WG; Patel MR; Lamanna N; Tsai DE; Nair B; Wang C; Zhao X; Liu D; Radtke D; Chapman S; Marella N; McNeely SC; Brown JR
    Blood; 2024 Sep; 144(13):1374-1386. PubMed ID: 38861666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.
    Innocenti I; Morelli F; Autore F; Tomasso A; Corbingi A; Bellesi S; Za T; De Stefano V; Laurenti L
    Leuk Lymphoma; 2019 Dec; 60(12):3078-3080. PubMed ID: 31106622
    [No Abstract]   [Full Text] [Related]  

  • 16. [Selective aplasia of the red-cell series after fludarabine administration in a patient with chronic B-cell lymphatic leukemia].
    Antich Rojas J; Balaguer H; Cladera A
    Sangre (Barc); 1997 Jun; 42(3):254-6. PubMed ID: 9381277
    [No Abstract]   [Full Text] [Related]  

  • 17. Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
    Wierda WG
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):214-216. PubMed ID: 31188811
    [No Abstract]   [Full Text] [Related]  

  • 18. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
    Jelinek T; Mihalyova J; Kascak M; Duras J; Popkova T; Benkova K; Richterova P; Plonkova H; Zuchnicka J; Broskevicova L; Huvarova L; Cerna L; Growkova K; Simicek M; Havel M; Gumulec J; Navratil M; Koristek Z; Paiva B; Hajek R
    Am J Hematol; 2019 Jan; 94(1):E35-E37. PubMed ID: 30370955
    [No Abstract]   [Full Text] [Related]  

  • 19. Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia.
    Stephens DM
    Blood; 2019 Nov; 134(20):1691-1696. PubMed ID: 31488409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
    Hampel PJ; Swaminathan M; Rogers KA; Parry EM; Burger JA; Davids MS; Ding W; Ferrajoli A; Hyak JM; Jain N; Kenderian SS; Wang Y; Wierda WG; Woyach JA; Parikh SA; Thompson PA
    Blood Adv; 2024 May; 8(10):2342-2350. PubMed ID: 38537065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.